Zentalis Pharmaceuticals (ZNTL) announced the appointment of Luke Walker, M.D., to its Board of Directors. Dr. Walker is the Chief Medical Officer of Harpoon Therapeutics, a subsidiary of Merck & Co. (MRK).
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZNTL:
- Zentalis Pharmaceuticals Announces Appointment of Accomplished Oncology Drug Developer Luke Walker, M.D., to Board of Directors
- Zentalis Pharmaceuticals to Present Promising Results from Phase 1 Trial of Azenosertib and Gemcitabine in Relapsed or Refractory Osteosarcoma at 2024 American Society of Clinical Oncology Annual Meeting
- Zentalis to present ‘promising’ Phase 1 trial data of Azenosertib at ASCO
- Zentalis Pharmaceuticals to Present at TD Cowen 5th Annual Oncology Innovation Summit
- Zentalis price target lowered to $40 from $46 at H.C. Wainwright